Ultragenyx Pharmaceutical Inc.
NASDAQ:RAREBiotechnology
+$0.81 today
- Market cap
- $1.81B
- Beta
- 0.38
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$6.06
Volume 5.16M
Average 1.81M
RARE EBITDA Margin
EBITDA as a percentage of revenue.
Ultragenyx Pharmaceutical Inc.NASDAQ: RARE
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to -114.0%
EBITDA Margin was -114.0% in Q1 FY2026, down 23.2 pp from a year earlier. On a trailing-twelve-month basis it was -75.2%, up 1.0 pp year over year. Over 3 fiscal years it widened by 105.9 pp.
Context
- EBITDA Margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 14 analysts of -2.5% for the fiscal year ending Dec 2026, up from -70.4% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -114.0%-65.6 pp QoQ
- Last fiscal yearDec 2025
- -70.4%+13.3 pp YoY
- LTMMar 2026
- -75.2%+1.0 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -70.4%
- Year-over-year change
- +13.3pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -70.4% | +13.3pp |
| FY2024 | 2024-12-31 | -83.7% | +35.2pp |
| FY2023 | 2023-12-31 | -118.9% | +57.4pp |
| FY2022 | 2022-12-31 | -176.3% | -59.5pp |
| FY2021 | 2021-12-31 | -116.8% | — |
EBITDA Margin vs competitors
How RARE compares with its peers on the latest reported figures
- RARE's LTM Mar 2026 EBITDA Margin of -75.2% is the 4th highest of the 10 companies compared; the peer median is -120.0%.
- Its year-over-year change of +1.0 pp is the 4th highest of 8, against a peer median of -30.5 pp.
- Over three fiscal years its change of +105.9 pp compares with a peer median of +257.8 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 505.0% | — | +3781.9 pp | |
| LTM Jun 2026 | 17.2% | -30.5 pp | +103.9 pp | |
| LTM Sep 2026 | -8.0% | -32.9 pp | +5.1 pp | |
| LTM Mar 2026 | -75.2% | +1.0 pp | +105.9 pp | |
| LTM Jun 2026 | -85.7% | +187.2 pp | +377.1 pp | |
| LTM Mar 2026 | -120.0% | +290.8 pp | +619.2 pp | |
| LTM Mar 2026 | -185.2% | +738962.6 pp | +3203.1 pp | |
| LTM Mar 2026 | -261.2% | -183.0 pp | +138.5 pp | |
| LTM Mar 2026 | -713.8% | -30.6 pp | -622.8 pp | |
| LTM Mar 2026 | -7858.4% | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding RARE) | -120.0% | -30.5 pp | +257.8 pp | |
Competitors are the stored peer set for RARE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 351.41M | 363.33M | 434.25M | 560.23M | 673M |
| Cost of Revenue | 16.01M | 28.32M | 45.21M | 76.73M | 109M |
| Gross Profit | 335.4M | 335.01M | 389.04M | 483.5M | 564M |
| Gross Margin | 95.4% | 92.2% | 89.6% | 86.3% | 83.8% |
| Research & Development | 497.15M | 705.79M | 648.45M | 697.87M | 750M |
| Selling, General & Admin | 219.98M | 278.14M | 309.8M | 321.61M | 349M |
| Operating Expenses | 717.14M | 983.93M | 958.25M | 1.02B | 1.1B |
| Depreciation & Amortization | 13.24M | 18.22M | 26.01M | 35.54M | 35M |
| EBITDA | (410.32M) | (640.49M) | (516.45M) | (469M) | (474M) |
| EBITDA Margin | -116.8% | -176.3% | -118.9% | -83.7% | -70.4% |
| Operating Income | (381.74M) | (648.92M) | (569.21M) | (535.97M) | (535M) |
| Operating Margin | -108.6% | -178.6% | -131.1% | -95.7% | -79.5% |
| Interest Income | 1.93M | 11.07M | 26.69M | 36.51M | 25M |
| Interest Expense | 29.42M | 43.02M | 66M | 63.04M | 62M |
| Other Income / Expenses | (71.24M) | (52.81M) | (39.26M) | (31.61M) | (36M) |
| Income Before Tax | (452.98M) | (701.73M) | (608.46M) | (567.59M) | (571M) |
| Pre-Tax Margin | -128.9% | -193.1% | -140.1% | -101.3% | -84.8% |
| Income Tax Expense | 1.04M | 5.7M | (1.83M) | 1.6M | 4M |
| Net Income | (454.03M) | (707.42M) | (606.64M) | (569.18M) | (575M) |
| Net Margin | -129.2% | -194.7% | -139.7% | -101.6% | -85.4% |
| EPS (Basic) | (6.70) | (10.12) | (8.25) | (6.29) | (5.83) |
| EPS (Diluted) | (6.70) | (10.12) | (8.25) | (6.29) | (5.83) |
| Weighted Avg Shares | 67.8M | 69.91M | 73.54M | 90.54M | 98.6M |
| Weighted Avg Shares (Diluted) | 67.8M | 69.91M | 73.54M | 90.54M | 98.6M |
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
Intrinsic Alpha fair value
Locked
Current Price
$17.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.